Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Leoben – page 5

426 clinical trials in Leoben, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Leoben at a glance
426
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

426 trials in Leoben

Open in trial search
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Doxepin hydrochloride
  • Sponsor:Medical University Of Graz

Safety and Pharmacokinetic Dose-Escalation Study of IMC-S118AI and Sodium Chloride in HLA‑A*02:01‑Positive Participants with Type 1 Diabetes

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:IMC S118AI
  • Sponsor:Immunocore Limited

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

Safety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Chiesi Farmaceutici S.p.A.

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Leoben

What the registry says about research in the country

01 Breast Cancer Research

Advanced clinical trials focusing on hormone receptor-positive breast cancer treatments, including studies of novel therapies for patients with high-risk disease profiles.

  • Node-positive ER+ HER2- breast cancer
  • Advanced breast cancer treatments
  • Endocrine therapy combinations

Multiple studies evaluating innovative therapeutic approaches for improving patient outcomes in early and advanced stages.

02 Lymphoma Studies

Comprehensive research into various types of lymphoma, examining new treatment combinations and comparing their effectiveness to standard therapies.

  • Follicular lymphoma
  • Diffuse Large B-cell Lymphoma
  • Hodgkin Lymphoma

Investigations focus on improving treatment responses while minimizing side effects.

03 Multiple Myeloma Research

Innovative trials exploring multiple myeloma treatments, including maintenance therapy approaches and combination treatments for both newly diagnosed and relapsed cases.

  • Newly diagnosed multiple myeloma
  • Relapsed/Refractory multiple myeloma
  • Combination therapy approaches

Studies aimed at improving treatment outcomes for various stages of the disease.

04 Leukemia & Other Blood Cancers

Research focusing on chronic lymphocytic leukemia and related blood disorders, evaluating novel therapeutic combinations.

  • Recurrent CLL treatments
  • Novel drug combinations
  • Treatment optimization

Trials designed to improve treatment outcomes for patients with recurring disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.